Avicanna (AVCN) Q2 2026 earnings summary

Executive summary

• Gross margin improved to 57% in Q2 2026, driven by a 48% quarterly increase in proprietary product sales.

• Proprietary QUIXTM rapid-onset portfolio is set for Q3 launch with over 35 commercial listings secured.

• Despite an 8% year-over-year revenue decline in Q2, underlying operations showed growth in proprietary product sales and patient/order volumes.

• The company navigated significant Veterans Affairs reimbursement changes while maintaining patient and order growth.

Financial highlights

• Q2 2026 revenue was $5.64 million, down 8% year-over-year; six-month revenue was $12.32 million, down 1%.

• Gross profit reached $3.19 million in Q2, with gross margin rising to 57% from 51% a year earlier.

• Adjusted EBITDA loss was $0.36 million in Q2, compared to a $0.25 million loss in Q2 2025.

• Working capital deficit reduced to $0.28 million as of June 30, 2026, from $1.28 million at year-end 2025.

Outlook and guidance

• Management expects revenue recovery, continued growth initiatives, and further operating efficiencies to support positive adjusted EBITDA in the second half of 2026.

• Continued portfolio expansion anticipated in Q3, including the launch of the QUIXTM portfolio.